The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis

Expert Opinion on Drug Safety

Volumn 3, Issue 6, 2004, Pages 525-534

  Bensimon, Gilbert ^a   Doble, Adam ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Adverse events (AEs); Amyotrophic lateral sclerosis (ALS); Riluzole; Transaminase

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; AMINOTRANSFERASE; AMITRIPTYLINE; AMOXICILLIN; BACLOFEN; CAFFEINE; CAPTOPRIL; CHLORZOXAZONE; CIMETIDINE; CLOMIPRAMINE; DIAZEPAM; DICLOFENAC; ENALAPRIL; ENOXACIN; IMIPRAMINE; KETOCONAZOLE; METHYLENE BLUE; METRONIDAZOLE; NICERGOLINE; OMEPRAZOLE; PARACETAMOL; PEFLOXACIN; PIRACETAM; PYRIDOXINE; QUINIDINE; RILUZOLE; UNINDEXED DRUG; XALIPRODEN;

ABDOMINAL PAIN; ACCIDENT; ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; APNEA; ARTHRALGIA; ASPIRATION PNEUMONIA; ASTHENIA; BACKACHE; BRONCHITIS; CLINICAL OBSERVATION; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEGENERATIVE DISEASE; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; DYSPHAGIA; DYSPNEA; ENZYME DEFECT; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRANULOCYTOPENIA; HEADACHE; HEART ARREST; HUMAN; HYPERSALIVATION; HYPERTENSION; INJECTION SITE; INJECTION SITE REACTION; INJURY; INSOMNIA; JAUNDICE; KIDNEY TUBULE DISORDER; LIPID DIET; LIVER DISEASE; LIVER FAILURE; LIVER METABOLISM; LIVER TOXICITY; LUNG DISEASE; METHEMOGLOBINEMIA; MUSCLE HYPERTONIA; MYASTHENIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PAIN; PANCREATITIS; PARESTHESIA; PATIENT MONITORING; PERIPHERAL EDEMA; PHARYNGITIS; PNEUMONIA; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RISK FACTOR; SOMNOLENCE; SPUTUM; SURVIVAL; SYNCOPE; TACHYCARDIA; TOXIC HEPATITIS; URINARY TRACT INFECTION; VERTIGO;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ASTHENIA; BIOTRANSFORMATION; CLINICAL TRIALS, PHASE IV; DISEASE PROGRESSION; DRUG INTERACTIONS; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; MIDDLE AGED; MULTICENTER STUDIES; NAUSEA; NEUTROPENIA; RANDOMIZED CONTROLLED TRIALS; RILUZOLE; RISK;

EID: 8844281519     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.6.525     Document Type: Review

References (40)

1. BROWN RH, MEININGER V. SWASH M: Amyotrophic lateral sclerosis. Martin Dunitz, London (2000).
2. BRUIJN LI, MILLER TM, CLEVELAND DW: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Ann. Rev Neurosci. (2004) 27:723-749.
3. SHAW CE, AL-CHALABI A, LEIGH N: Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr. Neurol. Acurosci. Rep. (2001) 1:69-76.
4. ROSEN DR, SIDDIQUE T, PATTERSON D et al.: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59-62.
5. DOBLE A: The pharmacology and mechanism of action of riluzole. Neurology (1996) 47(Suppl. 4):S233-S241.
6. BENSIMON G, LACOMBLEZ L, MEININGER V: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. (1994) 330:585-591.
7. LACOMBLEZ L, BENSIMON G, LEIGH PN et al.: A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology (1996) 47(Suppl. 4):S242-S250.
8. COURATIER P, DRUET-CABANAC M, TRUONG CT et al.: Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS. Rev. Neurol. (2000) 156:357-363.
9. TURNER MR, BAKKER M, SHAM P et al.: Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. Other Motor Neuron. Disord. (2002) 3 15-21.
10. TRAYNOR BJ, ALEXANDER M, CORR B et al.: An outcome study of riluzole in amyotrophic lateral sclerosis - a population-based study in Ireland, 1996-2000. J. Neurol. (2003) 250:473-479.
11. LEIGH PN, SWASH M, IWASAKI Y et al.: Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph. Lateral Scler. Other Motor Neuron. Disord. (2004) 5:84-98.
12. MILLER RG, MITCHELL JD, LYON M, MOORE DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. (2002) 2:CD001447.
13. LE LIBOUX A, LEFEBVRE P, LE ROUX Y et al.: Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J. Clin. Pharmacol. (1997) 37:820-827.
14. GROENEVELD GJ, VAN KAN HJ, KALMIJN S et al.: Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms. Neurology (2003) 61:1141-1143.
15. SANDERINK GJ, BOURNIQUE B, STEVENS J et al.: Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J. Pharmacol. Exp. Ther. (1997) 282:1465-1472.
16. LACOMBLEZ L, BENSIMON G, LEIGH PN et al.: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet (1996) 347 1425-1431.
17. REMY AJ, CAMU W, RAMOS J et al.: Acute hepatitis after riluzole administration. J. Hepatol. (1999) 30:527-530.
18. CASTELLS LI, GAMEZ J, CERVERA C, GUARDIA J: Icteric toxic hepatitis associated with riluzole. Lancet (1998) 351:648.
19. LACOMBLEZ L, DIB M, DOPPLER V et al.: Tolerance of riluzole in a Phase IIIb clinical trial. Therapie (2002) 57 65-71.
20. DEBOVE C, ZEISSER P, SALZMAN PM et al.: The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor. Neuron. Disord. (2001) 2:153-158.
21. LACOMBLEZ L, BENSIMON G, LEIGH PN et al.: Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2002) 3:23-29.
22. PONGRATZ D, NEUNDORFER B, FISCHER W: German open-label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. (2000) 180:82-85.
23. BENSIMON G, LACOMBLEZ L, DELUMEAU JC et al.: A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol. (2002) 249:609-615.
24. MEININGER V, BENSIMON G, BRADLEY WR et al.: Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two Phase III trials. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2004) 5:107-117.
25. DESNUELLE C, DIB M, GARREL C, FAVIER A: A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocoplierol Study Group. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2001) 2:9-18.
26. LE LIBOUX A, CACHIA JP, KIRKESSELI S et al.: A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. J. Clin. Pharmacol. (1999) 39:480-486.
27. BRUNO R, VIVIER N, MONTAY G et al.: Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin. Pharmacol. Ther. (1997) 62:518-526.
28. HAAS JF: The tolerability and adverse event profile of riluzole. Rev. Contemp. Pharmacother. (1998) 8:265-273.
29. RESTIVO DA, BIANCONI C, RAVENNI R, DE GRANDIS D: ALS and myasthenia: An unusual association in a patient treated with riluzole. Muscle Nerve. (2000) 23:294-295.
30. DRORY VE, SIDI I, KORCZYN AD: Riluzole-induced pancreatitis. Neurology (1999) 52:892-893.
31. POLONI TE, ALIMONTI D, MONTAGNA G et al.: Renal tubular impairment during riluzole therapy. Neurology (1999) 52:670.
32. NORTH WA, KHAN AM, YAMASE HT, SPORN JR: Reversible granulocytopenia in association with riluzole therapy. Ann. Pharmacother. (2000) 34:322-324.
33. VIALLON A, PAGE Y, BERTRAND JC: Methemoglobinemia due to riluzole. N. Engl. J. Med. (2000) 343:665-666.
34. RODRIGO L, MORENO M, CALLEJA S et al.: Riluzole-induced acute pancreatitis. Am. J. Gastroenterol. (2001) 96 2268-2269.
35. WEBER G, BITTERMAN H: Riluzole-induced neutropenia. Neurology (2004) 62:1648.
36. WOOLF A, CARSTAIRS SD, TANEN DA: Riluzole-induced methemoglobinemia. Ann. Emerg. Med. (2004) 43:294.
37. SCELSA SN, KHAN I: Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis. Eur. Neurol. (2000) 43:224-227.
38. MILLER RG, PETAJAN JH, BRYAN WW et al.: A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. (1996) 39:256-260.
39. LAI EC, FELICE KJ, FESTOFF BW et al.: Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology (1997) 49:1621-1630.
40. CUDKOWICZ ME, SHEFNER JM, SCHOENFELD DA et al.: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 61:456-464.